Hope For The Future

Pfizer's Abrysvo: A Game-Changer in RSV Prevention

Hope for the Future

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial MONeT evaluating two maternal vaccination schedules of its respiratory syncytial virus (RSV) vaccine candidate, RSVpreF.

A Breakthrough in RSV Prevention

RSV is a common, highly contagious respiratory virus that can cause severe illness in both older adults and infants. Currently, there is no approved vaccine available to prevent RSV infection in either population.

"These results are a significant milestone in our efforts to develop a safe and effective RSV vaccine for both older adults and infants," said Kathrin Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer.

Substudy B enrolled over 1,300 pregnant women who received two doses of either RSVpreF or placebo during the second and third trimesters of pregnancy. The results showed that RSVpreF was well-tolerated and induced robust immune responses in both mothers and infants.

In infants born to mothers vaccinated with RSVpreF, the vaccine was found to be highly effective in preventing severe RSV disease, with an efficacy of over 80%.

"These findings have the potential to revolutionize the way we prevent RSV infection in both older adults and infants," said Jansen. "We look forward to continuing the development of RSVpreF and bringing this important vaccine to patients as soon as possible."